GLYCEMIC DURABILITY OF ROSIGLITAZONE METFORMIN OR GLYBURIDE MONOTHERAPY PDF

METHODS: We evaluated rosiglitazone, metformin, and glyburide as initial treatment for recently diagnosed type 2 diabetes in a double-blind, randomized, controlled clinical trial involving patients. The patients were treated for a median of 4. The primary outcome was the time to monotherapy failure, w Queue ["Typeset",MathJax. The file s for this record are currently under an embargo.

Author:Bale Zutilar
Country:Pacific Islands
Language:English (Spanish)
Genre:Personal Growth
Published (Last):12 April 2016
Pages:473
PDF File Size:8.15 Mb
ePub File Size:14.60 Mb
ISBN:836-6-93519-964-5
Downloads:29851
Price:Free* [*Free Regsitration Required]
Uploader:Nilar



Background: The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known. Methods: We evaluated rosiglitazone, metformin, and glyburide as initial treatment for recently diagnosed type 2 diabetes in a double-blind, randomized, controlled clinical trial involving patients.

The patients were treated for a median of 4. The primary outcome was the time to monotherapy failure, which was defined as a confirmed level of fasting plasma glucose of more than mg per deciliter Prespecified secondary outcomes were levels of fasting plasma glucose and glycated hemoglobin, insulin sensitivity, and beta-cell function.

The difference in the durability of the treatment effect was greater between rosiglitazone and glyburide than between rosiglitazone and metformin. Conclusions: The potential risks and benefits, the profile of adverse events, and the costs of these three drugs should all be considered to help inform the choice of pharmacotherapy for patients with type 2 diabetes. This site needs JavaScript to work properly.

Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. Search: Search. Advanced Clipboard. Create file Cancel. Email citation To:. Format: Summary Summary text Abstract Abstract text. Send email Cancel. Add to Collections Create a new collection Add to an existing collection. Name your collection: Name must be less than characters. Choose a collection: Unable to load your collection due to an error Please try again.

Add Cancel. Add to My Bibliography My Bibliography. Unable to load your delegates due to an error Please try again. Your saved search Name of saved search:. Search terms:. Test search terms. Would you like email updates of new search results? Email: change. Frequency: Monthly Weekly Daily. Which day? Send at most: 1 item 5 items 10 items 20 items 50 items items items. Send even when there aren't any new results. Optional text in email:. Save Cancel. Create a file for external citation management software Create file Cancel.

Full-text links Cite Favorites. Erratum in N Engl J Med. Abstract Background: The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known. Comment in Thiazolidinediones for initial treatment of type 2 diabetes?

Nathan DM. N Engl J Med. Epub Dec 4. PMID: No abstract available. Glycemic durability of monotherapy for diabetes. Rathmann W, et al. Gandhi GY, et al. Parashar A, Varma A. Parashar A, et al. Garg R. Gaede P, Pedersen O.

Gaede P, et al. Nat Clin Pract Endocrinol Metab. Epub Apr ADOPT: lessons from comparison of glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. Yki-Jarvinen H. Curr Diab Rep. Liebson PR. Prev Cardiol. Dailey GE 3rd, et al. Am J Med. Scheen AJ. Rev Med Liege. Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial ADOPT. Kahn SE, et al.

Diabetes Care. Epub Oct 6. Clinical Trial. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Setter SM, et al. Clin Ther. PMID: Review. The "glitazones": rosiglitazone and pioglitazone. Papoushek C. J Obstet Gynaecol Can. Show more similar articles See all similar articles. Goodarzi MO, et al. Circ Res. Epub May PMID: Metformin and Its Benefits for Various Diseases.

Lv Z, Guo Y. Lv Z, et al. Front Endocrinol Lausanne. The impact of phenotype, ethnicity and genotype on progression of type 2 diabetes mellitus. Thakarakkattil Narayanan Nair A, et al. Endocrinol Diabetes Metab. Effective diabetes complication management is a step toward a carbon-efficient planet: an economic modeling study. Fordham R, et al. The effect of low and high dose empagliflozin on HbA1c and lipid profile in type 2 diabetes mellitus: A real-world data. Ozcelik S, et al. North Clin Istanb.

Show more "Cited by" articles See all "Cited by" articles. Publication types Comparative Study Actions. Multicenter Study Actions. Randomized Controlled Trial Actions. Research Support, Non-U.

Gov't Actions. Double-Blind Method Actions. Female Actions. Humans Actions.

LA76818A DATASHEET PDF

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

Skip to search form Skip to main content You are currently offline. Some features of the site may not work correctly. DOI: Kahn and Steven M. Haffner and Mark A. Holman and Nigel P.

CARTEA URANTIA PDF

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known. We evaluated rosiglitazone, metformin, and glyburide as initial treatment for recently diagnosed type 2 diabetes in a double-blind, randomized, controlled clinical trial involving patients. The patients were treated for a median of 4. The primary outcome was the time to monotherapy failure, which was defined as a confirmed level of fasting plasma glucose of more than mg per deciliter Prespecified secondary outcomes were levels of fasting plasma glucose and glycated hemoglobin, insulin sensitivity, and beta-cell function. The difference in the durability of the treatment effect was greater between rosiglitazone and glyburide than between rosiglitazone and met Continue Reading.

HYPERFREQUENCE COURS PDF

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy

Background: The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known. Methods: We evaluated rosiglitazone, metformin, and glyburide as initial treatment for recently diagnosed type 2 diabetes in a double-blind, randomized, controlled clinical trial involving patients. The patients were treated for a median of 4. The primary outcome was the time to monotherapy failure, which was defined as a confirmed level of fasting plasma glucose of more than mg per deciliter Prespecified secondary outcomes were levels of fasting plasma glucose and glycated hemoglobin, insulin sensitivity, and beta-cell function. The difference in the durability of the treatment effect was greater between rosiglitazone and glyburide than between rosiglitazone and metformin. Conclusions: The potential risks and benefits, the profile of adverse events, and the costs of these three drugs should all be considered to help inform the choice of pharmacotherapy for patients with type 2 diabetes.

ENCYCLOPEDIA OF SPIRITS JUDITH ILLES PDF

.

Related Articles